Hep C Meds Patent Row Can't Stay In Minn., Fed. Circ. Says
By Matthew Bultman ( January 17, 2018, 4:17 PM EST) -- The Federal Circuit on Wednesday refused to order that a patent lawsuit brought by the University of Minnesota against Gilead Sciences Inc. over hepatitis C medications be allowed to remain in the North Star State, leaving in place a ruling that found that storage lockers leased by Gilead did not create a place of business....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.